Commerzbank Aktiengesellschaft FI Purchases 183 Shares of Danaher Co. (NYSE:DHR)

Commerzbank Aktiengesellschaft FI raised its stake in Danaher Co. (NYSE:DHR) by 5.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,680 shares of the conglomerate’s stock after acquiring an additional 183 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Danaher were worth $920,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of DHR. Wetzel Investment Advisors Inc. bought a new stake in Danaher in the fourth quarter valued at $29,000. Lindbrook Capital LLC raised its position in shares of Danaher by 3.7% in the fourth quarter. Lindbrook Capital LLC now owns 4,832 shares of the conglomerate’s stock valued at $1,118,000 after purchasing an additional 171 shares during the period. Nicholas Hoffman & Company LLC. raised its position in shares of Danaher by 2.3% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after purchasing an additional 43 shares during the period. Handelsbanken Fonder AB raised its position in shares of Danaher by 4.6% in the fourth quarter. Handelsbanken Fonder AB now owns 306,534 shares of the conglomerate’s stock valued at $70,914,000 after purchasing an additional 13,609 shares during the period. Finally, Ramsay Stattman Vela & Price Inc. increased its holdings in Danaher by 2.2% during the 4th quarter. Ramsay Stattman Vela & Price Inc. now owns 70,873 shares of the conglomerate’s stock worth $16,396,000 after acquiring an additional 1,528 shares during the period. 79.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Linda Filler sold 3,928 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the transaction, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,707 shares of company stock valued at $10,786,944. Insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.2 %

DHR traded down $0.57 on Wednesday, reaching $271.09. The company’s stock had a trading volume of 1,087,498 shares, compared to its average volume of 2,834,835. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The stock has a 50 day moving average of $258.03 and a two-hundred day moving average of $253.96. The company has a market capitalization of $200.79 billion, a price-to-earnings ratio of 46.30, a P/E/G ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.05 earnings per share. As a group, analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Stifel Nicolaus upped their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. SVB Leerink increased their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Bank of America increased their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, Citigroup raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $276.88.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.